在急性冠状动脉综合征中使用比瓦利鲁丁
Mattia Galli1, Marco Bernardi2, Luis Ortega-Paz3
1Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Expert review of cardiovascular therapy
|November 3, 2023
概括
比瓦利鲁丁是一种直接的血栓抑制剂,在皮肤冠状动脉干预 (PCI) 期间,可减少急性冠状动脉综合征 (ACS) 患者的出血. 通过优化剂量,它可以减轻支架血栓形成风险,可能恢复其在ACS管理中的作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 比瓦利鲁丁是一种直接的血栓抑制剂,旨在最大限度地减少急性冠状动脉综合征 (ACS) 患者的出血,这些患者正在接受皮肤冠状动脉干预 (PCI).
- 尽管比未分离肝素 (UFH) 更有利的安全性,但由于担心增加支架血栓形成 (ST) 和成本,比瓦利鲁丁的使用受到限制.
- 以前的随机对照试验 (RCT) 有混因素,使得在ACS患者中比瓦利鲁丁和UFH之间的比较复杂化.
研究的目的:
- 重新评估比瓦利鲁丁在接受PCI的ACS患者中的作用.
- 评估最近的证据是否支持比瓦利鲁丁的更为突出的使用,考虑到其安全性和减少出血的好处.
主要方法:
- 审查最近的试验证据和现有的随机对照试验 (RCT) 关于在接受PCI的ACS患者中使用比瓦利鲁丁.
- 在以前的RCT中分析混因素,以及减轻急性支架血栓 (ST) 等风险的策略.
主要成果:
- 比瓦利鲁丁在出血方面表现出较高的安全性,与未分离的肝素 (UFH) 相比.
- 与比瓦利鲁丁相关的急性支架血栓形成 (ST) 的风险可以通过PCI后的全剂量输液方案有效管理.
- 有证据表明,比瓦利鲁丁可以安全地使用,而不会影响其有利的出血特征.
结论:
- 比瓦利鲁丁的优良安全性和降低出血的益处,值得在ACS治疗中加以考虑.
- 优化剂量策略可以减轻支架血栓形成的风险,使得比瓦利鲁丁在ACS患者的PCI手术中发挥更重要的作用.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Low-Molecular-Weight Heparins
719
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
719
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
535
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
535
Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9


